This research agreement is to test and determine the effect of AAGP on monoclonal antibody production and bone marrow recovery.
UBC's antibody lab will test whether AAGP enhances the production of monoclonal antibodies from cell lines, an important manufacturing issue for current immunotherapies.
UBC will also test whether AAGP enhances the survival/efficacy of engraftment of hematopoietic stem cells, a technical hurdle in cell based therapies for bone marrow transplantation and cancer therapy.
The goal will be to determine whether AAGP enhances the ex vivo survival and maintenance of multipotent potential in a way that could be used to enhance bone marrow transplantation.
ProtoKinetix has developed and patented a family of hyper stable, potent glycopeptides that enhance both engraftment and protection of transplanted cells used in regenerative medicine. The University of Alberta has begun Phase 1 human clinical trials.
Additional studies will be expanded to include whole organ transplantation and all therapies that are being developed globally to date including diabetes, retinal degeneration, cardiac repair, and other degenerative conditions.
In addition, The company is studying the potential impact on several cancer therapies.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Ionis Pharmaceuticals names new executive vice president, chief global product strategy officer
Hyperfine Inc and Athletic Heart collaborate to deliver portable brain imaging for former athletes
CSL reveals top-line outcome from Phase three AEGIS-II trial of CSL112
AstraZeneca invests USD300m to expand US manufacturing for cell therapy